Population Pharmacokinetic Analysis of Fluticasone Furoate/Umeclidinium Bromide/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease

Mehta Rashmi; Farrell Colm; Hayes Siobhan; Birk Ruby; Okour Malek; Lipson David A.

首页> 外文期刊>Clinical pharmacokinetics >Population Pharmacokinetic Analysis of Fluticasone Furoate/Umeclidinium Bromide/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease

【24h】

Population Pharmacokinetic Analysis of Fluticasone Furoate/Umeclidinium Bromide/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease

机译：慢性阻塞性肺疾病患者氟基呋喃酸盐/ UmeClidinium / Vilanterol的人口药代动力学分析

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background: Population pharmacokinetic methods were used to characterize the pharmacokinetics of fluticasone furoate (FF), umeclidinium (UMEC), and vilanterol (VI) in patients with chronic obstructive pulmonary disease (COPD) when administered as a fixed-dose combination via a single closed inhaler.

机译：背景：当通过单个闭合施用时，人口药代动力学方法用于表征慢性阻塞性肺疾病（COPD）患者的氟酮呋喃（FF），UMECLIDINIUM（UMEC）和Vilantolol（VI）的药代动力学吸入器。

著录项

来源
《Clinical pharmacokinetics》 |2020年第1期|共13页
作者
Mehta Rashmi; Farrell Colm; Hayes Siobhan; Birk Ruby; Okour Malek; Lipson David A.;
展开▼
作者单位

GSK Res Triangle Pk NC 27709 USA;

ICON Dev Solut Marlow Bucks England;

ICON Dev Solut Marlow Bucks England;

GSK Uxbridge Middx England;

GSK Collegeville PA USA;

GSK Collegeville PA USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类药理学;
关键词
COPD; Fluticasone furoate; Umeclidinium; Vilanterol; Population pharmacokinetics;

机译：COPD;氟替辛;UMECLIDINIUM;VILANTEROL;人口药代动力学;

相似文献

外文文献
中文文献
专利

1. Population Pharmacokinetic Analysis of Fluticasone Furoate/Umeclidinium Bromide/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease [J] . Mehta Rashmi, Farrell Colm, Hayes Siobhan, Clinical pharmacokinetics . 2020,第1期

机译：慢性阻塞性肺疾病患者氟基呋喃酸盐/ UmeClidinium / Vilanterol的人口药代动力学分析
2. Fluticasone furoate, umeclidinium bromide, and vilanterol as a combination therapy for chronic obstructive pulmonary disease [J] . Parri Giulia, Nieri Dario, Roggi Maria Adelaide, Expert review of respiratory medicine . 2018,第7a12期

机译：氟替辛呋喃，溴化物和维拉甾醇作为慢性阻塞性肺病的联合治疗
3. Triple Therapy of Fluticasone Furoate, Umeclidinium, Vilanterol- A Compelling Choice in Severe Chronic Obstructive Pulmonary Disease [J] . B Jagan Nathan, Melina I Sahay, AK Gautham, Journal of Clinical and Diagnostic Research . 2021,第2期

机译：Fluticasone Froate，Umeclidinium，Vilantolol-一种令人慢性慢性阻塞性肺病的引人注目的三重疗法
4. Moderate microvascular retinopathy predicts future cardiac events in a population of patients with chronic obstructive pulmonary disease [C] . Chew S., Hutchinson A., Colville D., World Congress on Heart Disease . 2012

机译：中度微血管视网膜病变预测慢性阻塞性肺病患者人口中未来的心脏事件
5. Comparative Effectiveness Research and Cost-Consequence Analysis of Albuterol and Levalbuterol in Patients with Chronic Obstructive Pulmonary Disease. [D] . Zhang, Yanjun. 2015

机译：慢性阻塞性肺疾病患者中沙丁胺醇和左沙丁胺醇的比较疗效研究和成本后果分析。
6. Single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol plus umeclidinium using two inhalers for chronic obstructive pulmonary disease: a randomized non-inferiority study [O] . Peter R. Bremner, Ruby Birk, Noushin Brealey, 2018

机译：单吸入器糠酸氟替卡松/乌米地林/维兰特罗与氟替卡松糠酸酯/维地洛尔加乌米地林使用两种吸入器治疗慢性阻塞性肺疾病：一项随机性非劣效性研究
7. InforMing the PAthway of COPD Treatment (IMPACT Trial) Single-Inhaler Triple Therapy (Fluticasone Furoate/Umeclidinium/Vilanterol) Versus Fluticasone Furoate/Vilanterol and Umeclidinium/Vilanterol in Patients With COPD: Analysis of the Western Europe and North America Regions [O] . Arnaud Bourdin, Gerard Criner, Gilles Devouassoux, 2021

机译：通知COPD治疗的途径（影响试验）单吸入器三重治疗（氟胺呋喃/ UmeClidinium / Vilanterol）与COPD患者的氟替辛呋喃/维尔替洛尔和Umeclidinium / Vilantolol：分析西欧和北美地区

Population Pharmacokinetic Analysis of Fluticasone Furoate/Umeclidinium Bromide/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease

摘要

著录项

相似文献

相关主题

期刊订阅